Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + everolimus
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Pazopanib + everolimus is a combination of two small molecule targeted therapies used primarily in oncology clinical trials. Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth factor receptor 3 (VEGFR3), platelet-derived growth factor receptor alpha, platelet-derived growth factor receptor beta, and c-Kit. This inhibits angiogenesis and tumor cell proliferation. Everolimus is an mTOR (mechanistic target of rapamycin) inhibitor that binds to FKBP-12 to inhibit mTORC1 activity, leading to reduced cell proliferation and angiogenesis. The combination aims to synergistically block both the VEGF pathway (angiogenesis) and the PI3K/AKT/mTOR pathway (cell growth/survival). It has been studied in advanced solid tumors including metastatic renal cell carcinoma and urothelial carcinoma[1][2][4].
- Brand names
- AfinitorVotrient
- Other names
- Votrient + AfinitorPazopanib and Everolimus combination
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)FKBP1AKIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)Mechanistic target of rapamycin complex 1VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on pazopanib + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + everolimus.